Bots, editor, reviewer, Administrators
13,941
edits
WikiJournalClub:Usable articles: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 82: | Line 82: | ||
* [[FAME]] (2009): FFR-guided PCI in stable CAD | * [[FAME]] (2009): FFR-guided PCI in stable CAD | ||
* [[FAME 2]] (2012): FFR-guided PCI vs. OMT in CAD | * [[FAME 2]] (2012): FFR-guided PCI vs. OMT in CAD | ||
* [[FREEDOM]] (2012): CABG vs. PCI for CAD in T2DM | |||
* [[FRISC-II]] (1999): Early invasive strategy in UA/NSTEMI | * [[FRISC-II]] (1999): Early invasive strategy in UA/NSTEMI | ||
* [[HOPE]] (2000): Ramipril in patients with high CV risk | * [[HOPE]] (2000): Ramipril in patients with high CV risk | ||
| Line 105: | Line 106: | ||
* [[BARI 2D]] (2009): CABG/PCI vs. OMT in diabetes with CAD | * [[BARI 2D]] (2009): CABG/PCI vs. OMT in diabetes with CAD | ||
* [[EMPA-REG OUTCOME]] (2015): Empagliflozin for CV outcomes in T2DM | * [[EMPA-REG OUTCOME]] (2015): Empagliflozin for CV outcomes in T2DM | ||
* [[FREEDOM]] (2012): CABG vs. PCI for CAD in T2DM | |||
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM | * [[Look AHEAD]] (2013): Weight loss and exercise in T2DM | ||
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM | * [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM | ||
| Line 382: | Line 384: | ||
'''Coronary Artery Disease''' | '''Coronary Artery Disease''' | ||
* [[BARI 2D]] (2009): CABG/PCI vs. OMT in diabetes with CAD | * [[BARI 2D]] (2009): CABG/PCI vs. OMT in diabetes with CAD | ||
* [[FREEDOM]] (2012): CABG vs. PCI for CAD in T2DM | |||
* [[WHI]] (2002): Postmenopausal estrogen/progesterone | * [[WHI]] (2002): Postmenopausal estrogen/progesterone | ||
| Line 393: | Line 396: | ||
* [[EDIC]] (2005): Intensive glycemic therapy in T1DM | * [[EDIC]] (2005): Intensive glycemic therapy in T1DM | ||
* [[EMPA-REG OUTCOME]] (2015): Empagliflozin for CV outcomes in T2DM | * [[EMPA-REG OUTCOME]] (2015): Empagliflozin for CV outcomes in T2DM | ||
* [[FREEDOM]] (2012): CABG vs. PCI for CAD in T2DM | |||
* [[IDNT]] (2001): ARBs in diabetic nephropathy | * [[IDNT]] (2001): ARBs in diabetic nephropathy | ||
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM | * [[Look AHEAD]] (2013): Weight loss and exercise in T2DM | ||